

## Invited review

## Hydrogen sulfide: third gaseous transmitter, but with great pharmacological potential

Chang-qing CHEN, Hong XIN, Yi-zhun ZHU<sup>1</sup>*Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 200032, China*

### Key words

hydrogen sulfide; cystathionine  $\beta$ -synthetase; cystathionine  $\gamma$ -lyase;  $K_{ATP}$  channels; capsaicin<sup>1</sup> Correspondence to Prof Yi-zhun ZHU.

Phn 86-21-5423-7077.

Fax 86-21-6404-2268.

E-mail zhuyz@shmu.edu.cn

Received 2007-01-02

Accepted 2007-03-19

doi: 10.1111/j.1745-7254.2007.00629.x

### Abstract

Hydrogen sulfide ( $H_2S$ ), which is well known traditionally as a toxic gas, has been proven to be produced endogenously by 3 enzymes in mammalian tissues and plays important roles in physiological and pathophysiological conditions. In the central nervous system,  $H_2S$  functions as not only a neuromodulator, but also a neuroprotectant against oxidative stress. In the cardiovascular system,  $H_2S$  relaxes vascular smooth muscles by the activation of  $K_{ATP}$  channels and inhibits smooth muscle cell proliferation via the mitogen-activated protein kinase signaling pathway. These effects are important for maintaining blood pressure and preventing vessel structural remodeling, and identifies  $H_2S$  as an important factor in the development of some vascular diseases, such as hypertension.  $H_2S$  also shows cardioprotective effects in ischemic myocardium and septic and endotoxin shock. Recent studies have demonstrated a new mechanism to explain the motor effect of  $H_2S$  on the rat detrusor muscle, which is through the activation of the capsaicin-sensitive primary neuron. This review focuses on the recent research achievements on  $H_2S$  and discloses the great potential of  $H_2S$  as the third gaseous transmitter in cardiac protection.

### Introduction

For hundreds of years, hydrogen sulfide ( $H_2S$ ) has been known solely as a toxic gas with the smell of rotten eggs. Indeed,  $H_2S$  is gradually considered to be a broad spectrum toxicant; its major toxic effects are the toxicity of the central nervous system (CNS) and the inhibition of the respiratory system<sup>[1,2]</sup>. Recent studies have shown that  $H_2S$  is not only a chemical hazard in certain industrial manufacturing, but it can also be produced endogenously in mammalian tissues from *L*-cysteine mainly by 3 enzymes: cystathionine  $\beta$ -synthetase (CBS), cystathionine  $\gamma$ -lyase (CSE), and 3-mercaptosulfurtransferase<sup>[3-6]</sup>. The expressions of CBS and CSE have been detected in various tissues.  $H_2S$  research has been recently focused on its physiological effects and significance under disease conditions. Like nitric oxide (NO) and carbon monoxide (CO), which are considered 2 gaseous transmitters,  $H_2S$  has been shown to be the third gaseous transmitter and plays important roles, both in normal physiology conditions and in the process/progress of several diseases.

$H_2S$  is a small molecule and can permeate membranes freely. The endogenous  $H_2S$  level is 0–46  $\mu\text{mol/L}$ <sup>[7]</sup> in rat serum and 50–160  $\mu\text{mol/L}$  in the brain<sup>[4]</sup>. One-third of  $H_2S$  remains undissociated in an aqueous solution and its solubility in lipophilic solvents is 5-fold greater than in water<sup>[8]</sup>.  $H_2S$  is mostly metabolized to sulfate and thiosulfate via the oxidation metabolism in mitochondria, and glutathione triggers the reaction. Very little of  $H_2S$  can be converted into lower toxic compounds of methylmercaptan and dimethyl sulfate via the methylation metabolism in cytosol. The metabolic product can exhaust from the kidney and intestinal tract and lungs within 24 h, so the endogenously-generated  $H_2S$  under physiological condition is hardly accumulated or toxic to cells due to the balanced cellular metabolism of the gas<sup>[9]</sup>.

Although there are several excellent reviews on the pathophysiological effects of  $H_2S$ , such as those by Wang<sup>[8]</sup> in 2002, Tang *et al*<sup>[6]</sup> and Du *et al*<sup>[10]</sup> in 2006, the present study will summarize the latest progress on  $H_2S$  studies concerning the CNS, cardiovascular system, a possible novel mecha-

nism for its motor effect, as well as the role of H<sub>2</sub>S in ischemia.

### Role of H<sub>2</sub>S in the CNS

Endogenous H<sub>2</sub>S is generated mainly by CBS in the brain<sup>[11]</sup>. The transcriptional expression of CBS, but not CSE, in the rat brain (hippocampus, cerebellum, cerebral, and brainstem) was confirmed using the Northern blot assay; a similar conclusion was confirmed in CBS knockout mice. The production of H<sub>2</sub>S by CBS in the brain is regulated by Ca<sup>2+</sup> and calmodulin<sup>[12]</sup>. It is greatly enhanced by the activation of glutamate receptors and electrical stimulation which could cause influx of Ca<sup>2+</sup>. There are 2 mechanisms through which CBS could produce H<sub>2</sub>S. First, CBS could catalyze the production of H<sub>2</sub>S from cysteine by a β-elimination or a α,β-elimination reaction; second, CBS can efficiently catalyze the formation of H<sub>2</sub>S via the condensation of homocysteine with cysteine, and the latter is not affected by Ca<sup>2+</sup> and calmodulin<sup>[13]</sup>. The regulation of CBS activity can affect brain H<sub>2</sub>S formation. Eto *et al* found that sodium nitroprusside (SNP), well known as a NO donor, could enhance CBS activity by modifying 4 of 13 cysteine residues of CBS, but this effect is independent of NO production<sup>[14]</sup>. A human CBS complete genomic sequence has been determined<sup>[15]</sup> and the transcriptional start sites of 5 CBS mRNA isoforms, designated CBS-1a–1e, have been mapped<sup>[16]</sup>. The 5 CBS transcripts begin with a different exon. CBS gene transcription might be regulated by more than 1 promoter. Isoforms -1a and -1b form the vast majority of transcripts. Regulation on the transcriptional level is likely to be the mechanism of the tissue-specific manner of CBS expression, and in some senses, the expression of CBS in the brain could be modulated at the gene level under physiological and pathophysiological conditions.

The endogenous H<sub>2</sub>S by CBS in the brain indicates it has physiological functions in the CNS. *N*-methyl-*D*-aspartate (NMDA) receptors may be one of its targets. The activation of NMDA receptors is required for the induction of hippocampal long-term potentiation (LTP)<sup>[17]</sup>, a synaptic model of learning and memory. Because of the relatively high concentration of endogenous H<sub>2</sub>S in the brain (50–160 μmol/L), the physiological concentration of H<sub>2</sub>S facilitates the induction of LTP by enhancing NMDA receptor-induced currents<sup>[11]</sup>. This activation could be blocked by an adenylyl cyclase-specific inhibitor, indicating that the modulation of NMDA receptors by H<sub>2</sub>S is induced by the enhancement of cAMP production<sup>[18]</sup>. This function ranked H<sub>2</sub>S as a neuromodulator in the brain. Another study showed that H<sub>2</sub>S could increase intracellular Ca<sup>2+</sup> and induce Ca<sup>2+</sup> waves in neighboring astrocytes<sup>[19]</sup>. Therefore, H<sub>2</sub>S may mediate signals between

neurons and glia and regulate synaptic activity by modulating the activity of both neurons and glia.

In addition to its role in signal transduction, H<sub>2</sub>S can protect neuron cells from oxidative stress, not only by increasing the levels of antioxidant glutathione<sup>[20]</sup>, but also by activating the K<sup>+</sup><sub>ATP</sub> and Cl<sup>-</sup> channels<sup>[21]</sup>. In human cultured neuron cells, H<sub>2</sub>S could inhibit peroxynitrite (ONOO<sup>-</sup>), which is an important mediator of human neurodegenerative disease, inducing tyrosine nitration, α1-antiproteinase inactivation, cell toxicity, intracellular protein oxidation, and protein nitration. This antioxidant action of H<sub>2</sub>S suggests it functions as an endogenous ONOO<sup>-</sup> scavenger<sup>[22]</sup>. Oxidative stress is responsible for neuronal damage and degenerates in brain disorders. These observations suggest that H<sub>2</sub>S may act as a neuroprotectant against oxidative stress.

The concentration of H<sub>2</sub>S in the brain changes with CNS diseases. The levels of H<sub>2</sub>S decreased by 55% in the brains of Alzheimer's disease (AD) patients and CBS activity was also dramatically decreased<sup>[23]</sup>, but the level of AdoMet, a CBS activator, is low in AD brains. The CBS activity was reduced in another disease, homocystinuria<sup>[24]</sup>. Febrile seizure (FS) frequently occurs in children. Both gamma-aminobutyric acid (GABA) B receptor (GABA<sub>B</sub>R) subunits and the H<sub>2</sub>S/CBS system were involved in FS. H<sub>2</sub>S functioned as a protective factor in the development of FS through regulating GABA<sub>B</sub>R<sup>[25]</sup>. Intriguingly, the levels of CBS in Down's syndrome brains were approximately 3 times greater than those in normal individuals<sup>[26]</sup>. The role of H<sub>2</sub>S in CNS diseases is not clear and needs to be explored in future. The progress of this field can provide novel therapy in clinical trials.

### Role of H<sub>2</sub>S in the cardiovascular system


Hosoki *et al* found that H<sub>2</sub>S could be generated in the homogenates of the portal vein and thoracic aorta<sup>[4]</sup>. They also identified that CSE was the major enzyme to generate H<sub>2</sub>S in these tissues by detecting the transcription of the mRNA of CSE with the Northern blot assay. The expression levels of CSE mRNA varied in different types of vascular tissues and was ranked as artery>aorta>tail artery>mesenteric artery<sup>[27]</sup>. A recent study has shown that in the heart, there is very few CBS, but plentiful CSE<sup>[28]</sup>. It seems that CBS does not play a major role in the cardiovascular system under physiological conditions. These observations suggested the potential physiological functions of H<sub>2</sub>S/the CSE system in the cardiovascular system. The biosynthetic underlying mechanism of action of H<sub>2</sub>S is summarized in Figure 1<sup>[3]</sup>.

H<sub>2</sub>S can be produced enzymatically in vascular tissues


and relaxes vascular smooth muscles both *in vivo* and *in vitro*<sup>[4,29]</sup>. This vasorelaxant effect is most probably caused by opening vascular smooth muscle cells (VSMC)  $K_{ATP}$  channels which leads to membrane hyperpolarization<sup>[27]</sup>. Therefore,  $H_2S$  may reduce extracellular  $Ca^{2+}$  entry and relax vascular tissues. The vasorelaxation induced by  $H_2S$  can be attenuated by the removal of the endothelium, since  $H_2S$  may facilitate the release of vasorelaxant factors from the endothelium, including NO and the endothelium-derived relaxing factor. As opposed to NO and CO,  $H_2S$ -induced vasorelaxation is not mediated by the cGMP signaling pathway. This indicates that  $H_2S$  is a novel endogenous gaseous modulator of vascular contractility. At the same time, similar to NO and CO,  $H_2S$  could inhibit VSMC proliferation and induce apoptosis *in vitro*<sup>[30,31]</sup>. Using cultured VSMC, exogenous  $H_2S$  could dose-dependently suppress the proliferation of VSMC through the mitogen-activated protein kinase (MAPK) signaling pathway. Studies using

molecular means to overexpress CSE in cultured VSMC found that endogenous  $H_2S$  could also attenuate the rate of cell proliferation and increase the rate of cell apoptosis. The effect is via the activation of MAPK and caspase-3. The possible signaling pathway is shown in Figure 2. So  $H_2S$  is not only a vasorelaxant, but also an important regulator of cell growth and may thereby attenuate the structural remodeling of vessel tissues. This can help us understand the mechanism of some vascular diseases and provide links to new therapeutic methods.

The pathophysiological role of  $H_2S$  in some cardiovascular diseases has been explored. The endogenous  $H_2S$ /CSE pathway participated in the pathophysiological process in vascular diseases, such as spontaneous hypertension<sup>[32]</sup>, hypoxia-induced pulmonary hypertension (HPH)<sup>[33-35]</sup>, and high pulmonary blood flow-induced pulmonary hypertension<sup>[36,37]</sup>. Hypertension is one of the most common cardiovascular diseases and its mechanism is not fully understood



**Figure 1.** Biosynthetic mechanism of action and principal biological effects of  $H_2S$ . Cystathionine  $\gamma$ -lyase (CSE) or cystathionine  $\beta$ -synthetase (CBS) catalyze the production of  $H_2S$  from cysteine in the donor cell. An influx of  $Ca^{2+}$ , perhaps triggered by the activation of NMDA receptors by glutamate or via separate channels, binds to calmodulin (CaM), thereby activating CBS. Factors that activate CSE have yet to be determined.  $H_2S$  is released, presumably by free diffusion, to act on the target cell to increase adenylyl cyclase (AC) activity, thereby raising the intracellular concentration of cAMP, and/or activating  $K_{ATP}$  channels directly to cause hyperpolarization (neurons) or smooth muscle relaxation. It should be noted that whether  $H_2S$  acts on a separate target cell or on the cell from which it is released (ie an autocrine effect) is not yet clear.  $H_2S$  is broken down either chemically or by sequestration with macromolecules, such as hemoglobin or glutathione. Major biological effects of released  $H_2S$  include smooth muscle relaxation and the promotion of neuronal long-term potentiation (LTP). Challenging questions that remain to be answered are indicated in green boxes<sup>[1]</sup>.



**Figure 2.** Schematic signal transduction pathways underlying the H<sub>2</sub>S-induced cell growth changes. “p” indicates the phosphorylated form.

yet. Vasoconstriction and structural remodeling by VSMC proliferation are essential processes in hypertension development. In the spontaneous hypertension rat model, the plasma level of H<sub>2</sub>S is low and the activity of CSE is suppressed. The exogenous administration of H<sub>2</sub>S not only attenuated the elevation of blood pressure and vessel remodeling, but also recovered the H<sub>2</sub>S level and CSE activity<sup>[32]</sup>. Guang *et al*'s study found that there was dysfunction of the H<sub>2</sub>S/CSE system in *L*-NAME-induced hypertension rats and that exogenous H<sub>2</sub>S could effectively prevent the development of hypertension<sup>[38]</sup>. The exogenous H<sub>2</sub>S-induced positive feedback on CSE activity is different from its negative feedback in physiological conditions<sup>[39]</sup>. A recent study reported that the exogenous administration of H<sub>2</sub>S downregulated osteopontin gene expression and ameliorated vascular calcification (which is a common finding in many diseases, such as hypertension, atherosclerosis, diabetes, chronic renal failure, aging, and arterial stenosis)<sup>[40]</sup>. As it is known, the baroreflex is the major method of blood pressure modulation. Exogenous H<sub>2</sub>S could facilitate carotid sinus baroreflex (CSB) by opening K<sub>ATP</sub> channels and further closing the calcium channels in vascular smooth muscle which suggests that endogenous H<sub>2</sub>S might activate the activity of the CSB *in vivo*<sup>[41]</sup>. In HPH pathophysiological processes, the similar dysfunction of H<sub>2</sub>S/CSE was found, and exogenous H<sub>2</sub>S could inhibit the proliferative cell nuclear antigen (PCNA) and U-II expressions in the pulmonary wall to depress the proliferation of pulmonary artery smooth muscle cells and reduce the expression of collagen I and III, elastin, and TGF-β3 to decrease the hypoxic pulmonary vascular structural remodeling<sup>[34,35]</sup>. Olson *et al*'s recent study on the mechanical and electrical responses of select blood vessels to hypoxia and H<sub>2</sub>S suggested that H<sub>2</sub>S served as an O<sub>2</sub> sensor/transducer in the vascular responses to hypoxia. The inhibi-

tion of H<sub>2</sub>S synthesis inhibited the hypoxic response of vertebrate blood vessels and the concentration of H<sub>2</sub>S in the vessel was regulated by the balance between endogenous H<sub>2</sub>S production and its oxidation by available O<sub>2</sub><sup>[42]</sup>. The exogenous supply of H<sub>2</sub>S could alleviate the elevation of pulmonary arterial pressure. At the same time, exogenous supply of propargylglycine (PPG, inhibitor of CSE), plasma CO level, and the expressions of the HO-1 protein and mRNA in pulmonary arteries decreased. The results showed that H<sub>2</sub>S could play a regulatory role in the pathogenesis of HPH through the upregulation of the CO/HO pathway<sup>[43]</sup>. However, in aortic smooth muscle cells, Jin *et al*'s study proved that endogenous CO/HO and the H<sub>2</sub>S/CSE pathways downregulated each other under physiological conditions<sup>[44]</sup>. Exogenous H<sub>2</sub>S also ameliorated pulmonary vascular structural remodeling induced by high pulmonary blood flow, downregulated PCNA expression and the ERK/MAPK signal pathway, inhibited the NO/NO synthase pathway, and enhanced the CO/HO pathway in rats with high pulmonary blood flow<sup>[36,37]</sup>. These studies suggested that endogenous H<sub>2</sub>S was one of the key factors in hypertension development and that the deficit of the H<sub>2</sub>S/CSE system was one of the major causes of hypertension.

Some studies have proven that the concentration of arterial endogenous H<sub>2</sub>S was significantly increased in both septic and endotoxic shock rats, which suggested that endogenous H<sub>2</sub>S was still involved in physiological and pathophysiological processes during shock<sup>[45]</sup>.

Human cystathioninuria, which is characterized by high plasma homocysteine and cystathionine, is concerned with a wide range of disease associations, such as cardiovascular injury. Its genomic basis has been shown to be 2 non-sense mutations and 2 sense mutations in CSE<sup>[46]</sup>.

It has been reported that H<sub>2</sub>S also activates the K<sub>ATP</sub> channel in mitochondria and sarcolemmal K<sub>ATP</sub> channels in cardiac myocytes and has potent cardioprotective effects<sup>[47-49]</sup>. The cardioprotection of H<sub>2</sub>S was also demonstrated in rat isolated ventricular myocytes<sup>[50]</sup>. NaHS could concentration-dependently increase the cell viability and the percentage of rod-shaped cells, which were exposed to severe metabolic inhibition solution. NaHS-induced cardioprotection following metabolic inhibition preconditioning could be blocked by PPG and HMR-1098 (a sarcolemmal K<sub>ATP</sub> blocker). Pretreatment with *L*-NAME to block endogenous NO production could also attenuate the cardioprotective effect of NaHS. These results indicate that H<sub>2</sub>S may protect the heart most probably by activating sarcolemmal K<sub>ATP</sub>, which is different from its vasorelaxant effect. NO also plays an important role in cardioprotection. Further, the cardioprotective


effect has similar characteristics to the time-course of ischemic preconditioning; it suggests the possible protective role of H<sub>2</sub>S in ischemic myocardium. This has been proven by a recent study<sup>[51]</sup>. In a rat model of myocardial infarction (MI), NaHS treatment could decrease the mortality rate of MI rats and diminish infarct size as shown in Figure 3. The vessel dilating/relaxing effects of NaHS may dilate coronary arteries and increase coronary blood flow in ischemic diseases, thus reducing cellular damage from ischemia. This heart protective effect could be abolished by the administration of PPG. The results were further con-

firmed by our *in vitro* hypoxic model (Figure 4). It has been suggested that endogenous H<sub>2</sub>S might provide a novel approach to the treatment of MI. Further work needs to be performed to explore whether or not the mechanism of this effect concerns the K<sub>ATP</sub> channel. H<sub>2</sub>S also showed a cardioprotective effect in another isoproterenol injection-induced myocardial ischemic injury model in which the plasma H<sub>2</sub>S concentration and CSE activity decreased. The administration of NaHS could effectively protect myocytes and contractile activity<sup>[52]</sup>.


### Excitatory motor effect of H<sub>2</sub>S

In contrast to the vasorelaxant effect, NaHS produced concentration-dependent contractile responses in the detrusor muscle of the rat urinary bladder<sup>[53]</sup>. This response exhibited rapid and persistent tachyphylaxis similar to the responses of capsaicin<sup>[54,55]</sup>. The response was abolished by high-capsaicin pretreatment which could desensitize capsaicin-sensitive primary afferent neurons or the pretreatment of tissues with a combination of tachykinin natural killer (NK)<sub>1</sub> and NK<sub>2</sub> receptor-selective antagonists. At the same time, the response to NaHS is mostly resistant to tetrodotoxin, as is the effect of capsaicin in this organ<sup>[56]</sup>. These results show pharmacological evidence that H<sub>2</sub>S stimulates capsaicin-sensitive primary afferent nerve terminals with the consequent release of tachykinins, which in turn produces contractile responses of the detrusor muscle. In further studies, the same researchers demonstrated that the transient receptor potential vanilloid receptor 1 (TRPV1, also called the capsaicin receptor) selective antagonist capsazepine and SB366791 could not affect the H<sub>2</sub>S contractile activity<sup>[53]</sup>. However, the unselective cation channel blocker, ruthenium red, almost abolished the contraction similar to its effect on capsaicin, which provided 2 hypotheses: first, H<sub>2</sub>S stimulates the TRPV1 receptor by a different way from those known activators; second, H<sub>2</sub>S might stimulate other receptors present on the terminals of capsaicin-sensitive sensory neurons.

TRPV1 was cloned from rat sensory neurons<sup>[57]</sup> in 1997. TRPV1 is non-selective cation channel with high permeability of Ca<sup>2+</sup> and could be activated by chemical and physical stimuli, such as capsaicin, low pH<sup>[58]</sup>, noxious heat, anandamide<sup>[59]</sup>, 12-hydroperoxyeicosatetraenoic acid<sup>[60]</sup>, and *N*-arachidonoyl-dopamine<sup>[61]</sup>. The influx of Na<sup>+</sup> causes primary sensory neuron depolarization and the initiation of action potentials. In particular, the influx of Ca<sup>2+</sup> resulted in the local release of neuropeptides, including the calcitonin gene-related peptide and the tachykinins, substance P, and neurokinin A. TRPV1-positive neurons are not only afferent



**Figure 3.** Mortality and myocardial infarct size changes in vehicle, PPG, and NaHS pretreatment groups. <sup>b</sup>*P*<0.05 infarct size in NaHS group vs vehicle and PPG-treated groups; <sup>e</sup>*P*<0.05 infarct size in PPG group vs vehicle and NaHS-treated groups. <sup>i</sup>*P*<0.05 mortality in NaHS group vs vehicle and PPG-treated groups. Figure modified with permission from Zhu *et al*<sup>[51]</sup>.



**Figure 4.** (A) VSMC viability measurement in control (non-hypoxia) and hypoxic vehicle, and NaHS and PPG pretreatment groups. (B) relative LDH liberation in control (non-hypoxia) and hypoxic vehicle, and NaHS, and PPG pretreatment groups. <sup>b</sup>*P*<0.05 hypoxic vehicle vs control; <sup>e</sup>*P*<0.05 NaHS-treated vs vehicle; <sup>i</sup>*P*<0.05 PPG vs NaHS-treated). Figure modified with permission from Zhu *et al*<sup>[51]</sup>.

neurons which are involved in the perception of somatic and visceral pain, but also have a sensory effector function. These neuropeptides act on different effector cells and cause different responses, including neurogenic inflammation, thermal hyperalgesia, airway constriction, and vasodilatation<sup>[62]</sup>. TRPV1 is highly expressed in primary sensory neurons of the trigeminal, vagal, and dorsal root ganglion with C- and A- $\delta$  fibers, which are called nociceptive neuron. Studies also show that TRPV1 is expressed in non-neuronal cells, including epithelial cells of the urothelium<sup>[63]</sup>, keratinocytes<sup>[64]</sup>, and skeletal muscles<sup>[65]</sup>. These features of TRPV1 indicate its broad physiological and pathophysiological functions.

In addition to the detrusor muscle, NaHS increases sensory neuropeptide release in the guinea pig airways and causes *in vivo* bronchoconstriction and microvascular leakage in a capsazepine-sensitive manner<sup>[66]</sup>. This novel mechanism may contribute to the irritant action of H<sub>2</sub>S in the respiratory system, possibly through TRPV1 activation. Further research is still required in order to prove whether or not H<sub>2</sub>S acts as an endogenous ligand of TRPV1. It will be interesting to detect the odorous activator of TRPV1 and its undergoing mechanism. Therefore, previous studies on the physiological and pathophysiological roles of H<sub>2</sub>S need re-evaluation based on this mechanism.

## Concluding remarks

H<sub>2</sub>S has been shown to be an important biological molecule in the last 2 decades. In addition to its neuromodulator and cardiovascular protection effects, studies also show that H<sub>2</sub>S has various effects in mammalian tissues, such as the relaxation effect of the ileum, which indicates that endogenous H<sub>2</sub>S could regulate alimentary contractile functions<sup>[67]</sup>. H<sub>2</sub>S has been described as an endogenous mediator with diverse biological effects in a study, including playing an important role in endotoxin-induced inflammation<sup>[68]</sup>. The studies of the physiological functions of H<sub>2</sub>S and its underlying mechanism, the regulation of H<sub>2</sub>S concentration and activity, and/or the expression of CBS and/or CSE and its interaction with some diseases may have a significant impact in our understanding of the pathogenesis of these diseases, as well as having far-reaching clinical and therapeutic implications. Further research needs to be undertaken to find new therapeutic methods and ruling out possible side-effects.

## References

- 1 Beauchamp RJ, Bus JS, Popp JA, Boreiko CJ, Andjelkovich DA. A critical review of the literature on hydrogen sulfide toxicity. *Crit Rev Toxicol* 1984; 13: 25–97.
- 2 Guidotti TL. Hydrogen sulphide. *Occup Med (Lond)* 1996; 46: 367–71.
- 3 Moore PK, Bhatia M, Moochhala S. Hydrogen sulfide: from the smell of the past to the mediator of the future? *Trends Pharmacol Sci* 2003; 24: 609–11.
- 4 Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. *Biochem Biophys Res Commun* 1997; 237: 527–31.
- 5 Kimura H, Nagai Y, Umemura K, Kimura Y. Physiological roles of hydrogen sulfide: synaptic modulation, neuroprotection, and smooth muscle relaxation. *Antioxid Redox Signal* 2005; 7: 795–803.
- 6 Tang CS, Li XH, Du JB. Hydrogen sulfide as a new endogenous gaseous transmitter in the cardiovascular system. *Curr Vasc Pharmacol* 2006; 4: 17–22.
- 7 Zhao W, Ndisang JF, Wang R. Modulation of endogenous production of H<sub>2</sub>S in rat tissues. *Can J Physiol Pharmacol* 2003; 81: 848–53.
- 8 Wang R. Two's company, three's a crowd: can H<sub>2</sub>S be the third endogenous gaseous transmitter? *FASEB J* 2002; 16: 1792–8.
- 9 Furne J, Springfield J, Koenig T, DeMaster E, Levitt MD. Oxidation of hydrogen sulfide and methanethiol to thiosulfate by rat tissues: a specialized function of the colonic mucosa. *Biochem Pharmacol* 2001; 62: 255–9.
- 10 Du JB, Zhang CY, Yan H, Tang CS. A newly found gasotransmitter, hydrogen sulfide, in the pathogenesis of hypertension and other cardiovascular diseases. *Curr Hypertens Rev* 2006; 2: 123–6.
- 11 Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. *J Neurosci* 1996; 16: 1066–71.
- 12 Eto K, Kimura H. The production of hydrogen sulfide is regulated by testosterone and S-adenosyl-L-methionine in mouse brain. *J Neurochem* 2002; 83: 80–6.
- 13 Chen X, Jhee KH, Kruger WD. Production of the neuromodulator H<sub>2</sub>S by cystathionine beta-synthase via the condensation of cysteine and homocysteine. *J Biol Chem* 2004; 279: 52082–6.
- 14 Eto K, Kimura H. A novel enhancing mechanism for hydrogen sulfide-producing activity of cystathionine beta-synthase. *J Biol Chem* 2002; 277: 42680–5.
- 15 Avila MA, Berasain C, Torres L, Martin-Duce A, Corrales FJ, Yang H, *et al*. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. *J Hepatol* 2000; 33: 907–14.
- 16 Bao L, Vlcek C, Paces V, Kraus JP. Identification and tissue distribution of human cystathionine beta-synthase mRNA isoforms. *Arch Biochem Biophys* 1998; 350: 95–103.
- 17 Harris EW, Ganong AH, Cotman CW. Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors. *Brain Res* 1984; 323: 132–7.
- 18 Kimura H. Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. *Biochem Biophys Res Commun* 2000; 267: 129–33.
- 19 Nagai Y, Tsugane M, Oka J, Kimura H. Hydrogen sulfide induces calcium waves in astrocytes. *FASEB J* 2004; 18: 557–9.
- 20 Kimura Y, Kimura H. Hydrogen sulfide protects neurons from oxidative stress. *FASEB J* 2004; 18: 1165–7.
- 21 Kimura Y, Dargusch R, Schubert D, Kimura H. Hydrogen sulfide

- protects HT22 neuronal cells from oxidative stress. *Antioxid Redox Signal* 2006; 8: 661–70.
- 22 Whiteman M, Cheung NS, Zhu YZ, Chu SH, Siau JL, Wong BS, *et al*. Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? *Biochem Biophys Res Commun* 2005; 326: 794–8.
- 23 Eto K, Asada T, Arima K, Makifuchi T, Kimura H. Brain hydrogen sulfide is severely decreased in Alzheimer's disease. *Biochem Biophys Res Commun* 2002; 293: 148–58.
- 24 Hu FL, Gu Z, Kozich V, Kraus JP, Ramesh V, Shih VE. Molecular basis of cystathionine beta-synthase deficiency in pyridoxine responsive and nonresponsive homocystinuria. *Hum Mol Genet* 1993; 2: 1857–60.
- 25 Han Y, Qin J, Bu DF, Chang XZ, Yang ZX, Du JB. Gamma-aminobutyric acid B receptor regulates the expression of hydrogen sulfide/cystathionine-beta-synthase system in recurrent febrile seizures. *Zhongguo Dang Dai Er Ke Za Zhi* 2006; 8: 141–3 Chinese.
- 26 Ichinohe A, Kanaumi T, Takashima S, Enokido Y, Nagai Y, Kimura H. Cystathionine beta-synthase is enriched in the brains of Down's patients. *Biochem Biophys Res Commun* 2005; 338: 1547–50.
- 27 Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H<sub>2</sub>S as a novel endogenous gaseous K(ATP) channel opener. *EMBO J* 2001; 20: 6008–16.
- 28 Geng B, Yan H, Zhong GZ, Zhang CY, Chen XB, Jiang HF, *et al*. Hydrogen sulfide: a novel cardiovascular functional regulatory gas factor. *Beijing Da Xue Xue Bao* 2004; 36: 106. Chinese.
- 29 Zhao W, Wang R. H(2)S-induced vasorelaxation and underlying cellular and molecular mechanisms. *Am J Physiol Heart Circ Physiol* 2002; 283: 474–80.
- 30 Du JB, Yan H, Cheung YF, Geng B, Jiang HF, Chen XB, *et al*. The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. *Heart Vessels* 2004; 19: 75–80.
- 31 Yang G, Sun X, Wang R. Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3. *FASEB J* 2004; 18: 1782–4.
- 32 Yan H, Du JB, Tang CS. The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. *Biochem Biophys Res Commun* 2004; 313: 22–7.
- 33 Zhang C, Du J, Bu DB, Yan H, Tang X, Si Q, *et al*. The regulatory effect of endogenous hydrogen sulfide on hypoxic pulmonary hypertension. *Beijing Da Xue Xue Bao* 2003; 35: 488–93. Chinese.
- 34 Li XH, Du JB, Shi L, Li J, Tang XY, Qi JG, *et al*. Down-regulation of endogenous hydrogen sulfide pathway in pulmonary hypertension and pulmonary vascular structural remodeling induced by high pulmonary blood flow in rats. *Circ J* 2005; 69: 1418–24.
- 35 Jin HF, Cong BL, Zhao B, Zhang CY, Liu XM, Zhou WJ, *et al*. Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling. *Life Sci* 2006; 78: 1299–309.
- 36 Wang YF, Shi L, Du JB, Tang CS. Impact of L-arginine on hydrogen sulfide/cystathionine-γ-lyase pathway in rats with high blood flow-induced pulmonary hypertension. *Biochem Biophys Res Commun* 2006; 345: 851–7.
- 37 Li XH, Du JB, Bu DF, Tang XY, Tang CS. Sodium hydrosulfide alleviated pulmonary vascular structural remodeling induced by high pulmonary blood flow in rats. *Acta Pharmacol Sin* 2006; 27: 977–86.
- 38 Zhong GZ, Chen FR, Cheng YQ, Tang CS, Du JB. The role of hydrogen sulfide in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase. *J Hypertens* 2003; 21:1879–85.
- 39 Kredich NM, Foote LJ, Keenan BS. The stoichiometry and kinetics of the inducible cysteine desulfhydrase from *Salmonella typhimurium*. *J Biol Chem* 1973; 248: 6187–96.
- 40 Wu SY, Pan CS, Geng B, Zhao J, Yu F, Pang YZ, *et al*. Hydrogen sulfide ameliorates vascular calcification induced by vitamin D3 plus nicotine in rats. *Acta Pharmacol Sin* 2006; 27: 299–306.
- 41 Xiao L, Wu YM, Zhang H, Liu YX, He RR. Hydrogen sulfide facilitates carotid sinus baroreflex in anesthetized rats. *Acta Pharmacol Sin* 2006; 27: 294–8.
- 42 Olson KR, Dombkowski RA, Russell MJ, Doellman MM, Head SK, Whitfield NL, *et al*. Hydrogen sulfide as an oxygen sensor/transducer in vertebrate hypoxic vasoconstriction and hypoxic vasodilation. *J Exp Biol* 2006; 209: 4011–23.
- 43 Zhang QY, Du JB, Zhou WJ, Yan H, Tang CS, Zhang CY. Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of hypoxic pulmonary hypertension. *Biochem Biophys Res Commun* 2004; 317: 30–7.
- 44 Jin HF, Du JB, Li XH, Wang YF, Liang YF, Tang CS. Interaction between hydrogen sulfide/cystathionine gamma-lyase and carbon monoxide/heme oxygenase pathways in aortic smooth muscle cells. *Acta Pharmacol Sin* 2006; 27: 1561–6.
- 45 Yan H, Du JB, Tang CS, Geng B, Jiang HF. Changes in arterial hydrogen sulfide (H<sub>2</sub>S) content during septic shock and endotoxin shock in rats. *J Infect* 2003; 47: 155–60.
- 46 Wang J, Hegele RA. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). *Hum Gene* 2003; 112: 404–8.
- 47 Geng B, Yang J, Qi Y, Zhao J, Pang Y, Du JB, *et al*. H<sub>2</sub>S generated by heart in rat and its effects on cardiac function. *Biochem Biophys Res Commun* 2004; 313: 362–8.
- 48 O'Rourke B. Pathophysiological and protective roles of mitochondrial ion channels. *J Physiol* 2000; 529: 23–36.
- 49 Gross GJ, Fryer RM. Sarcolemmal versus mitochondrial ATP-sensitive K<sup>+</sup> channels and myocardial preconditioning. *Circ Res* 1999; 84: 973–9.
- 50 Pan TT, Feng ZN, Lee SW, Moore PK, Bian JS. Endogenous hydrogen sulfide contributes to the cardioprotection by metabolic inhibition preconditioning in the rat ventricular myocytes. *J Mol Cell Cardiol* 2006; 40: 119–30.
- 51 Zhu YZ, Wang ZJ, Ho P, Loke YY, Zhu YC, Huang XW, *et al*. Hydrogen sulfide and its cardioprotective effects in myocardial ischemia in experimental rats. *J Appl Physiol* 2006; 102: 261–8.
- 52 Geng B, Chang L, Pan C, Qi Y, Zhao J, Pang Y, *et al*. Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. *Biochem Biophys Res Commun* 2004; 318: 756–63.
- 53 Patacchini R, Santicioli P, Giuliani S, Maggi CA. Pharmacological investigation of hydrogen sulfide (H<sub>2</sub>S) contractile activity in rat detrusor muscle. *Eur J Pharmacol* 2005; 509: 171–7.
- 54 Maggi CA, Santicioli P, Giuliani S, Furio M, Meli A. The capsaicin-sensitive innervation of the rat urinary bladder: further stud-

- ies on mechanisms regulating micturition threshold. *J Urol* 1986; 136: 696–700.
- 55 Birder LA, Apodaca G, De Groat WC, Kanai AJ. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. *Am J Physiol* 1998; 275: 226–9.
- 56 Maggi CA, Patacchini R, Giachetti A, Meli A. Tachykinin receptors in the circular muscle of the guinea-pig ileum. *Br J Pharmacol* 1997; 101: 996–1000.
- 57 Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* 1997; 389: 816–24.
- 58 Tominaga M, Numazaki M, Iida T, Moriyama T, Togashi K, Higashi T, *et al.* Regulation mechanisms of vanilloid receptors. *Novartis Found Symp* 2004; 261: 4–12.
- 59 Zygmunt PM, Julius I, Di Marzo I, Hogestatt ED. Anandamide—the other side of the coin. *Trends Pharmacol Sci* 2000; 21: 43–4.
- 60 Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, *et al.* Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. *Proc Natl Acad Sci USA* 2000; 97: 6155–60.
- 61 Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, *et al.* An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. *Proc Natl Acad Sci USA* 2002; 99: 8400–5.
- 62 Wimalawansa SJ. Antihypertensive effects of oral calcium supplementation may be mediated through the potent vasodilator CGRP. *Am J Hypertens* 1993; 6: 996–1002.
- 63 Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, *et al.* Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. *Nat Neurosci* 2002; 5: 856–60.
- 64 Inoue K, Koizumi S, Fuziwara S, Denda S, Inoue K, Denda M. Functional vanilloid receptors in cultured normal human epidermal keratinocytes. *Biochem Biophys Res Commun* 2002; 291: 124–9.
- 65 Xin H, Tanaka H, Yamaguchi M, Takemori S, Nakamura A, Kohama K. Vanilloid receptor expressed in the sarcoplasmic reticulum of rat skeletal muscle. *Biochem Biophys Res Commun* 2005; 332: 756–62.
- 66 Trevisani M, Smart D, Gunthorpe MJ, Tognetto M, Barbieri M, Campi B, *et al.* Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. *Nat Neurosci* 2002; 5: 546–51.
- 67 Teague B, Asiedu S, Moore PK. The smooth muscle relaxant effect of hydrogen sulphide *in vitro*: evidence for a physiological role to control intestinal contractility. *Br J Pharmacol* 2002; 137: 139–45.
- 68 Li L, Bhatia M, Zhu YZ, Zhu YC, Ramnath RD, Wang ZJ, *et al.* Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. *FASEB J* 2005; 19: 1196–8.